FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Change Platform Technology Guidance: Stakeholders

[ Price : $8.95]

Three stakeholders ask FDA to modify a draft guidance on the agencys platform technology designation guidance.

5 CGMP Observations in CARsgen Inspection

[ Price : $8.95]

FDA warns Durham, NC-based CARsgen Therapeutics about CGMP violations in its production of investigational drugs and biologics use...

EUA for Freeze-Dried Plasma for Military Use

[ Price : $8.95]

Federal Register notice: FDA announces the issuance of an emergency use authorization for Octapharmas freeze-dried plasma product,...

EyePoint Pharmaceuticals GCMP Violations

[ Price : $8.95]

FDA warns Watertown, MA-based EyePoint Pharmaceuticals about CGMP violations in its production of finished drugs.

Illuminas TrusSight Test OK'd as Companion Diagnostic

[ Price : $8.95]

FDA approves an llumina PMA for its in vitro diagnostic TruSight Oncology Comprehensive test for two companion diagnostic indicati...

FDA Tightens Pemgarda Covid-19 EUA

[ Price : $8.95]

FDA explains its rationale for making six changes to the emergency use authorization for Invivyds Pemgarda Covid-19 pre-exposure p...

FDA Expanding RWD/RWE Use: Marston

[ Price : $8.95]

FDA chief medical officer Hilary Marston explains in a podcast how the agency is expanding its use of real-world data and evidence...

Ractigen Gets Orphan Status for Duchennes

[ Price : $8.95]

FDA grants Ractigen Therapeutics an orphan drug designation for RAG-18 and its use in treating Duchenne Muscular Dystrophy.

Amgens Blincyto Gets Expanded Approval

[ Price : $8.95]

FDA approves Amgens Blincyto (blinatumomab) for treating adult and pediatric patients with CD19-positive Philadelphia chromosome-n...

Excela Diltiazem Not Withdrawn for Safety/Efficacy

[ Price : $8.95]

Federal Register notice: FDA determines that Exela Pharma Sciences diltiazem HCl in dextrose, 125mg/125mL and 250mg/250mL were not...